VAIM GLOBAL Unveils New Findings on 'JUVELOOK' for Photoaging and Pigmentation Treatment

VAIM GLOBAL Unveils New Findings on 'JUVELOOK' for Photoaging and Pigmentation Treatment

Recent paper on Juvelook has been published in international academic journal Experimental Dermatology. The paper demonstrated positive effects in treating photoaging pigmentation disorders such as melasma and senile lentigines.

The study involved 40 female participants with symptoms of photoaging pigmentation, aiming to validate the therapeutic effects of PDLLA (Poly-D,L-lactic acid). The research team employed a split-face comparative study method, injecting PDLLA on one side of the participants' faces and saline solution on the other side to observe the degree of skin improvement.

The results demonstrated significant improvements in the participants' melasma and senile lentigines. Notably, the skin brightness value on the PDLLA-treated side increased markedly compared to the control group after four weeks of treatment, with the effects lasting up to 12 weeks. Additionally, histopathological biopsies and image analysis revealed that PDLLA significantly enhanced fibroblast activity, promoting collagen synthesis and contributing to improved skin elasticity.

A representative from VAIM GLOBAL said, "This study confirms that JUVELOOK not only excels in skin regeneration but also serves as an effective treatment for photoaging pigmentation disorders. We have identified the potential of JUVELOOK for various indications and will continue to invest in research and development to further expand its clinical applications."

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM Global, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM Global currently has product export contracts with 72 countries.